Search results
FDA Advisers Like Lilly’s Alzheimer’s Drug. It’s Good News for Biogen.
Barrons.com· 3 days agoStill, it’s certainly not bad...Chen wrote Monday. It’s even more significant for Biogen and Eisai....
Biophytis Announces Filing of an IND Application with the US FDA for its Phase 2 Study in Obesity
Digital Journal· 5 days agoFood and Drug Administration (FDA) regarding its phase 2 OBA clinical study in obesity with BIO101 ...
Is Eli Lilly Stock A Buy After FDA Advisors Back Its Alzheimer's Drug?
Investor's Business Daily· 3 days agoMost of the time ARIA is temporary and asymptomatic. But the Food and Drug Administration's advisors...
Common low-calorie sweetener linked to heart attack and stroke, study finds
CNN.com· 3 hours agoA low-calorie sweetener called xylitol used in many reduced-sugar foods and consumer products such...
Eli Lilly stock hits all-time high: What’s been driving the pharma giant’s share price higher?
Bankrate via Yahoo Finance· 2 days agoHowever, investors should remain cautious. The full impact of donanemab on the Alzheimer’s treatment...
Common low-calorie sweetener linked to heart attack and stroke, study finds
CNN via Yahoo News· 3 hours agoA common low-calorie sweetener called xylitol, found in gum, candy, toothpaste and more, may cause...
Experimental GLP-1 med may be breakthrough against fatty liver disease
Medical Xpress· 4 days agoThe drug under development, survodutide, helped up to 83% of patients gain real improvements in...
MDMA, Juul and a cardiovascular disease study. 3 health stories you may have missed — and why they...
Yahoo Life Style via AOL· 6 days agoObesity, which is also linked to cardiovascular issues, is on the rise, including with...The good...
Lilly Alzheimer’s drug gets unanimous backing of FDA panel
BioPharma Dive via Yahoo Finance· 4 days agoCurrently, the average analyst estimate has donanemab generating close to $5 billion in annual sales...
Syntis Bio launches oral therapies for metabolic diseases
Pharmaceutical Technology via Yahoo Finance· 2 days agoThe company's lead obesity programme, SYNT-101, is currently undergoing human...other rare disease...